Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Legend Biotech is a clinical-stage biopharmaceutical company commercializing CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma, developed in partnership with Johnson & Johnson. The company operates manufacturing facilities in the US and Belgium to support commercial production, with revenue driven by CARVYKTI sales following FDA approval in February 2022 and subsequent label expansions. Stock performance is highly sensitive to clinical trial readouts for earlier-line multiple myeloma indications, manufacturing capacity expansion, and competitive dynamics in the CAR-T oncology landscape.
Legend generates revenue through commercial sales of CARVYKTI, splitting profits with J&J under their collaboration agreement. The autologous CAR-T manufacturing process involves collecting patient T-cells, genetically modifying them to target BCMA on myeloma cells, expanding the modified cells, and infusing them back into patients. Pricing power is substantial given the therapy's efficacy in heavily pre-treated patients (list price approximately $465,000 per treatment), though limited by payer negotiations, manufacturing capacity constraints, and competition from Bristol Myers Squibb's Abecma and emerging therapies. Gross margins of 63% reflect the complex, personalized manufacturing process with high fixed costs at production facilities in New Jersey and Ghent, Belgium.
CARVYKTI quarterly sales performance versus consensus estimates and sequential growth trajectory
Clinical trial data readouts for CARTITUDE-4 (second-line multiple myeloma) and other earlier-line studies that could expand addressable market from ~10,000 to ~40,000+ patients annually
Manufacturing capacity announcements and vein-to-vein time improvements that signal ability to meet demand without slot constraints
Competitive developments from Bristol Myers Squibb (Abecma, CC-92480), Caribou Biosciences (allogeneic CAR-T), and other BCMA-targeted therapies
FDA regulatory decisions on label expansions and manufacturing site approvals
Technological disruption from allogeneic (off-the-shelf) CAR-T therapies that eliminate patient-specific manufacturing, reduce costs, and improve accessibility - companies like Caribou Biosciences and Allogene are advancing programs that could commoditize autologous approaches
Competitive pressure from bispecific antibodies (J&J's Tecvayli, Pfizer's elranatamab) and antibody-drug conjugates that offer simpler administration without apheresis/manufacturing logistics, potentially capturing market share in earlier treatment lines
Manufacturing scalability challenges inherent to autologous cell therapy - each batch is patient-specific, limiting economies of scale and creating supply bottlenecks that could cap revenue growth below market potential
Bristol Myers Squibb's Abecma has first-mover advantage in the BCMA CAR-T space and is advancing in earlier-line settings with CARTITUDE-4 competitor trials
Johnson & Johnson partnership dynamics create dependency - J&J controls commercialization strategy and could prioritize other assets in its oncology portfolio, while profit-sharing reduces Legend's economics relative to fully-owned products
Negative free cash flow of $200M annually with current market cap of $1.7B creates equity dilution risk if additional capital raises are needed before achieving profitability
Stock price decline of -53% over past year significantly impairs ability to raise capital on favorable terms, potentially forcing dilutive financing or partnership concessions
low - Cancer treatment demand is largely non-discretionary and insulated from economic cycles. However, hospital capital budgets for cell therapy infrastructure and payer reimbursement policies can be indirectly affected during severe recessions. Multiple myeloma patient volumes are driven by disease epidemiology rather than GDP growth.
Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as investors discount future cash flows at higher rates, making current losses more expensive. Legend's $200M annual cash burn and reliance on capital markets for funding creates refinancing risk if rates remain elevated, though the current 2.86x current ratio and moderate 0.41 debt/equity ratio provide near-term cushion. Higher rates also increase opportunity cost for growth investors, pressuring the stock's 1.8x price/sales multiple.
Moderate - while Legend's own credit needs are manageable with current liquidity, broader credit tightening could affect hospital systems' ability to invest in CAR-T infrastructure (apheresis centers, patient monitoring capabilities) and potentially delay therapy adoption. Payer reimbursement stability is critical given the $465,000 per-patient price point.
growth - investors are betting on CARVYKTI's potential to capture significant share of the $8B+ multiple myeloma market as it moves into earlier treatment lines, despite current negative profitability. The 120% revenue growth rate and large addressable market expansion opportunity attract biotech growth specialists willing to tolerate high volatility and binary clinical/regulatory risk. Recent -53% drawdown has likely attracted some contrarian value investors betting on oversold conditions, but core holder base remains growth-focused given negative earnings and cash flow.
high - as a clinical-stage biotech with single-product revenue concentration, the stock exhibits extreme volatility around clinical trial readouts, FDA decisions, and quarterly sales beats/misses. Beta likely exceeds 1.5x given the -53% annual decline against broader market performance. Binary outcomes from CARTITUDE-4 trial results could drive 30-50% single-day moves in either direction.